Exclusive Summary

• **[Note]** Specific drug name missing in input; this analysis serves as a strategic framework for high-value pharmaceutical licensing. Please insert the specific drug name for actual use.
• **Strategic Market Timing**: Targets the 'Patent Cliff' post-Loss of Exclusivity (LOE) of the originator, offering a timely entry point to capture market share or replace high-cost therapies.
• **Integrated Supply Chain & Cost Efficiency**: Leverages China's vertical integration (API + FDF), ensuring supply stability and a 30-50% cost advantage over Western originators.
• **Institutional Endorsement**: The introduction by Deyi Capital implies strong R&D backing and financial solvency, reducing due diligence risks for potential overseas licensors.

Asset Materials

Contact Us for Full Materials